GlassScriptPhysician profile
James Connolly
NPI 1609255223
$5,009.88
in general payments reported to CMS, 2019-2025
31 companies · $1,836 in 2025
The $1,836 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $859 · 2023: $1,137 · 2024: $1,177 · 2025: $1,836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109 · Education: $41.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,109.14 |
| Education | $41.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $825.00 | 2022-2025 | Entyvio |
| Abbvie INC. | $636.33 | 2022-2025 | Linzess, Viberzi, Creon |
| Janssen Biotech, INC. | $573.41 | 2023-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $328.01 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $265.14 | 2024-2025 | Livdelzi |
| Janssen Scientific Affairs, LLC | $240.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.45 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $186.52 | 2023-2025 | |
| Medtronic, INC. | $158.75 | 2023 | Interstim |
| Olympus America INC. | $148.54 | 2022 | |
| Neuraxis, INC. | $146.32 | 2025 | |
| Celltrion USA INC. | $127.40 | 2024 | Zymfentra |
| Genzyme Corporation | $125.59 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.99 | 2023 | Zeposia |
| Aimmune Therapeutics, INC. | $109.71 | 2023-2025 | Vowst |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $102.14 | 2022 | |
| Celgene Corporation | $101.86 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $83.44 | 2022-2023 | Sucraid |
| Madrigal Pharmaceuticals | $80.18 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $65.20 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $64.29 | 2024-2025 | Rebyota |
| Organon LLC | $51.37 | 2023-2024 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $50.35 | 2023-2025 | Iqirvo, Bylvay |
| Daiichi Sankyo INC. | $48.88 | 2023-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $27.79 | 2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $26.74 | 2023 | |
| Orphalan INC | $20.80 | 2025 | Cuvrior |
| Lilly USA, LLC | $19.97 | 2023 | Zepbound, Jardiance |
| Ardelyx, INC. | $16.90 | 2024 | Ibsrela |
| Braintree Laboratories, INC. | $16.08 | 2024 | Suflave, Sutab |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.